Urinary hydroxyproline in multiple myeloma: correlation with clinical stages and bone disease.
Twenty-four-hour urinary hydroxyproline excretion (HOP) (normal values: 6-22 mg/day/m2) was measured by the Hypronosticon test in 50 untreated patients with plasma cell myeloma. At diagnosis, HOP was elevated in 36 of 50 patients (72%) with a mean value of 35.9 mg/day/m2. Extent of bone lesions and clinical stage were accurately assessed in all patients. Higher HOP values were found in patients with a higher degree of bone lesions (multiple lytic areas and/or destruction of skeletal segments). According to clinical stages, HOP was very elevated only in stage III (mean value: 43.7); in stages I and II the mean value (25.2) was just above the normal range. Our data indicate that HOP in multiple myeloma at diagnosis is closely related to the extension of skeletal lesions and that during the clinical course it may be useful in the follow-up of bone disease.
D000328:Adult; D000368:Aged; D001847:Bone Diseases / Q000209:etiology / Q000652:urine*; D005260:Female; D050723:Fractures, Bone / Q000652:urine; D006801:Humans; D006909:Hydroxyproline / Q000652:urine*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications / Q000473:pathology / Q000652:urine*; D009367:Neoplasm Staging; D010014:Osteolysis / Q000652:urine; D010024:Osteoporosis / Q000652:urine
D006909:Hydroxyproline